#China #Shanghai #Sanyou Bio #ADCs #NovoCodex

Strategic Collaboration Between Sanyou Bio and NovoCodex

In a groundbreaking development in biopharmaceuticals, Sanyou Biopharmaceuticals and NovoCodex have announced a strategic partnership aimed at co-developing innovative dual-payload antibody-drug conjugates (ADCs). This collaboration seeks to harness the unique strengths of both companies to enhance cancer therapeutics globally.

The Power of Collaboration

As cancer treatments evolve, the demand for more effective and targeted therapies increases. Sanyou Bio, known for its robust capabilities in antibody discovery powered by its AI-Super trillion antibody/molecule libraries (AI-STAL) and the Sanyou AI-Drug Accelerator (SAI-DA), is partnering with NovoCodex, which specializes in site-specific conjugation technology using unnatural amino acids. Together, they aim to drive the development of ADCs that are not only innovative but also have a higher clinical value for patients.

NovoCodex’s proprietary NovoCode™ platform is a game-changer. It allows for the precise incorporation of unnatural amino acids into antibodies, resulting in homogeneous ADCs—a stark contrast to traditional methods that often produce heterogeneous mixtures. This technology has already been validated in a pivotal Phase III clinical trial, ensuring its effectiveness and reliability.

Unique Development Capabilities

Since its inception in 2020, Sanyou Bio has completed over 800 successful ADC conjugation projects. They are notably recognized for their innovation in the development of dual-target and dual-payload ADCs. These novel formats enhance the targeting capability of ADCs while expanding their therapeutic window. By integrating these capabilities with NovoCodex’s advanced conjugation technology, the partners believe they can unlock new potential in ADC design and effectiveness.

Key Focus Areas of the Collaboration

1. Integration of Antibody Discovery Technology: By utilizing the AI-STAL platform, Sanyou Bio will identify antibody candidates that exhibit superior internalization efficiency and target specificity. Simultaneously, NovoCodex will refine the conjugation processes to ensure a seamless evaluation of both antibody characteristics and conjugation strategies.

2. Exploration of Dual-Target and Dual-Payload ADCs: The collaboration will advance the evaluation of combinations for dual-target ADCs and explore pairs for dual-payload ADCs. Preclinical proof-of-concept studies will also be a significant focus.

3. Building a Closed-Loop Research and Development Workflow: A joint project team will be established to integrate every stage of the development process, from antibody screening to in vitro and in vivo evaluations, ensuring a streamlined approach that enhances the speed and efficiency of ADC candidate development.

Industry Insights

Dr. Xuejun Liang, CEO of NovoCodex, emphasized that the success of ADCs significantly depends on how well antibody molecules can interact with the chosen conjugation strategy. He expressed confidence that this collaboration would elevate their capabilities, bridging the gap between molecular design and practical development.

Dr. Guojun Lang, the Founder and CEO of Sanyou Bio, reiterated the value of NovoCodex's conjugation technology. He noted that its precise control over conjugation sites will enable a swifter transition from engineering concepts to actual therapeutic candidates, fulfilling unmet needs in cancer treatment.

Future Perspectives

This strategic partnership marks a significant milestone for both companies as they strengthen their positions in the competitive biopharmaceutical landscape. By leveraging their complementary strengths in ADC development, Sanyou Bio and NovoCodex aim to push the boundaries of current therapies and accelerate the delivery of effective treatments to cancer patients worldwide.

Both companies remain committed to innovation, collaboration, and the advancement of cutting-edge ADC therapeutics, and their partnership underscores an important shift in how cancer therapies are developed, emphasizing efficiency and effectiveness.

About the Companies

Sanyou Biopharmaceuticals is dedicated to solving the complexities of drug development, focusing on innovative treatment solutions. Based in Shanghai, China, they have built a global network and established partnerships with over 2,000 companies.

NovoCodex specializes in cutting-edge biological innovations and is known for its advanced conjugation technologies. The duo's collaboration is set to reshape the future of ADCs in oncology, promising a new era of targeted cancer therapies.